HHS opens interim 503A compounding path for six peptides
Three months after the FDA's Pharmacy Compounding Advisory Committee recommended six research peptides for the 503A bulk drug substances list, the Department of Health and Human Services has moved first. On October 28, 2026, HHS filed a Federal Register notice of availability for an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Doc. 2026-22192), scheduled for publication on October 30. The policy does not approve the peptides, does not finish the bulks-list rulemaking, and does not green-light 503B outsourcing facilities. What it does say is narrower and still material: while FDA develops the 503A list through rulemaking, HHS does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities, or licensed physicians who compound listed peptide bulk drug substances under the policy's conditions. For a research community that has lived through Category 2 removals, advisory votes, and unresolved rulemaking timelines, this is the first post-PCAC federal statement that changes the near-term compounding enforcement picture.
What HHS actually announced
The Federal Register filing is a notice of availability, not a final rule adding substances to 21 CFR 216.23. HHS describes a draft enforcement-discretion policy that applies while the 503A bulks list is developed through notice-and-comment rulemaking under section 503A of the FD&C Act. Compounded drugs remain unapproved; FDA does not review them for safety, effectiveness, or quality before marketing. The policy’s stated rationale is patient access where approved products are unavailable, paired with an explicit reservation that HHS may revisit the policy if safety signals or product-quality issues arise.
The six peptides on Appendix A
Appendix A names six bulk drug substances: BPC-157, Epitalon (Epithalon), KPV, MOTS-c, Semax, and TB-500. These are the same six that received favorable PCAC recommendations in July 2026 after FDA staff had recommended against listing. Emideltide (DSIP), which PCAC did not recommend, is not on Appendix A. That alignment matters: the interim policy tracks the advisory committee’s yes votes rather than inventing a broader wellness-peptide free-for-all.
Route, identity, and quality conditions
Appendix B and the policy body go beyond a name list. Covered forms are specific by salt and route. Compounders must match the stated identity and route limits. Bulk substance is expected from an FDA-registered establishment under section 510, accompanied by a valid certificate of analysis. Legal summaries also describe patient-specific prescriptions and adverse-event reporting expectations. Missing any required circumstance takes the activity outside the stated discretion.
What the policy does not do
Enforcement discretion is not FDA approval. None of the six becomes an approved new drug by virtue of this notice. The policy does not place the substances on the final 503A bulks list. It is not a 503B pathway. It also does not legalize research-use-only gray-market distribution, change WADA status, or rewrite foreign regulators’ rules. HHS itself states the document establishes no rights and is not binding in the manner of a legislative rule.
How this relates to the July 2026 PCAC votes
On July 23–24, 2026, PCAC recommended six of seven nominated peptides for the 503A bulks list and did not recommend DSIP. Those votes were advisory. The October policy is the first major federal bridge between those recommendations and day-to-day 503A enforcement posture. It does not replace rulemaking; it temporarily shapes enforcement while rulemaking proceeds.
International and enforcement context remains mixed
Outside the United States, the picture did not flip with this filing. Australia’s TGA continues to treat many unapproved peptide products as compliance priorities. UK MHRA activity has focused heavily on unlicensed weight-loss medicines. Domestically, GLP-1 compounding remains on a different regulatory path from these six research peptides. The HHS peptide policy should not be conflated with compounded semaglutide or tirzepatide rules.
What researchers should watch next
First, docket comments under HHS-OASH-2026-0496. Second, whether HHS revises Appendix A or B or withdraws discretion if safety signals appear. Third, FDA’s actual proposed and final rules on each bulk substance. Fourth, state pharmacy board implementation. Until final rules publish, the accurate description is conditional interim discretion for six named bulk substances under stated safeguards — not a general peptide legalization.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.